BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18292509)

  • 21. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
    Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
    Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner.
    Lautwein A; Kraus M; Reich M; Burster T; Brandenburg J; Overkleeft HS; Schwarz G; Kammer W; Weber E; Kalbacher H; Nordheim A; Driessen C
    J Leukoc Biol; 2004 May; 75(5):844-55. PubMed ID: 14966190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing.
    Bellemare-Pelletier A; Tremblay J; Beaulieu S; Boulassel MR; Routy JP; Massie B; Lapointe R; Thibodeau J
    J Leukoc Biol; 2005 Jul; 78(1):95-105. PubMed ID: 15817706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
    Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
    J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct protease requirements for antigen presentation in vitro and in vivo.
    Matthews SP; Werber I; Deussing J; Peters C; Reinheckel T; Watts C
    J Immunol; 2010 Mar; 184(5):2423-31. PubMed ID: 20164435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands.
    Honey K; Nakagawa T; Peters C; Rudensky A
    J Exp Med; 2002 May; 195(10):1349-58. PubMed ID: 12021314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endosomal aspartic proteinases are required for invariant-chain processing.
    Marić MA; Taylor MD; Blum JS
    Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2171-5. PubMed ID: 8134367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens.
    Cheng PC; Steele CR; Gu L; Song W; Pierce SK
    J Immunol; 1999 Jun; 162(12):7171-80. PubMed ID: 10358163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
    Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
    J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain.
    Rajagopalan G; Smart MK; Krco CJ; David CS
    J Immunol; 2002 Aug; 169(4):1774-83. PubMed ID: 12165499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The lysosomal cysteine proteases in MHC class II antigen presentation.
    Hsing LC; Rudensky AY
    Immunol Rev; 2005 Oct; 207():229-41. PubMed ID: 16181340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular transport of MHC class II and associated invariant chain in antigen presenting cells from AP-3-deficient mocha mice.
    Sevilla LM; Richter SS; Miller J
    Cell Immunol; 2001 Jun; 210(2):143-53. PubMed ID: 11520080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
    Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
    J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
    Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
    Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor.
    Podolin PL; Bolognese BJ; Carpenter DC; Davis TG; Johanson RA; Fox JH; Long E; Dong X; Marquis RW; Locastro SM; Terfloth GJ; Kurali E; Peterson JJ; Smith BR; McQueney MS; Yamashita DS; Capper-Spudich EA
    J Immunol; 2008 Jun; 180(12):7989-8003. PubMed ID: 18523262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
    Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
    J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
    Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
    Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.